Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion PotentialTipRanks Financial Blog • 25 days ago
Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Femasys (FEMY Research Report). The associated price target remains the...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Femasys (NASDAQ:FEMY - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of...
Following FDA Clearance of FemaSeed , Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys...
Femasys (NASDAQ:FEMY Free Report) had its price objective hoisted by Jonestrading from $7.00 to $10.00 in a research note published on Wednesday morning, Benzinga reports. The brokerage...
Chardan Capital reissued their buy rating on shares of Femasys (NASDAQ:FEMY Free Report) in a research note released on Thursday, Benzinga reports. The firm currently has a $12.00 price...
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed at 1PM ET...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI...